Business Wire

PLANETS-CO-LTD

18.11.2022 18:01:38 CET | Business Wire | Press release

Share
teamLab Planets TOKYO: Tickets purchased from overseas have increased by 136% compared to the same month in 2019 (before the COVID-19 pandemic), with one in three visitors coming from overseas

teamLab Planets is a museum where visitors walk through water, and a garden where people become one with the flowers. The experiential museum has welcomed a cumulative total of over 3 million visitors since its opening in July 2018.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005639/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

teamLab, Floating Flower Garden; Flowers and I are of the Same Root, the Garden and I are One © teamLab

[Several new areas introduced during the pandemic]

Despite the impact of the coronavirus pandemic in 2020, various new areas have opened at the museum as featured on notable media such as CNN during the pandemic, including two large-scale artworks in the Garden Area, and an adjoining vegan ramen restaurant originating from Kyoto.

[Increase in foreign visitors due to the lifting of the ban on individual travel to Japan and the expansion of new areas]

On October 11, 2022, the Japanese government significantly eased the COVID-19 border measures. The ban on individual travel to Japan has been lifted, visa exemptions have returned and the daily limit on the number of people entering Japan has been removed. In response, tourism to Japan has resumed properly for the first time in about two and a half years.

Around a month since the lifting of the ban on individual travel to Japan on October 11, tickets purchased by visitors from overseas increased by 136% compared to the same month in 2019 (before COVID-19), with one in three visitors coming from overseas. (*1)
More than half of the visitors from overseas purchased their tickets before visiting Japan, and a trend has been seen in which the museum is one of the purposes for people to visit Tokyo. (*2)
In the visitor questionnaire, there have been positive comments from visitors from overseas, such as "I've been wanting to go to the museum since the renewal."

(*1) According to ticket purchase data from the teamLab Planets official website: survey period - October 11 (Tue) to November 6 (Sun), 2022, and October 11 (Fri) to November 6 (Wed) 2019
(*2) According to ticket purchase data from the teamLab Planets official website: survey period - October 11 (Tue) and November 6 (Sun), 2022

[High praise from travel magazines]

In recent years the museum has been featured in notable publications such as Lonely Planet, a world-famous travel guidebook, which introduced it as one of “The 7 best museums in Tokyo that even Tokyoites line up for”, as well as in “The 26 Best Things to Do in Tokyo” by Condé Nast Traveler.

We look forward to welcoming visitors that are sightseeing in Tokyo to experience the museum, which has evolved through new artwork spaces.

The museum will continue to provide people from around the world an experience based on the concept of teamLab Planets, “Immerse your Body, and with Others, Become One with the World”.

Garden Area

The Garden Area was unveiled in July 2021 featuring two large-scale artworks, including a garden with over 13,000 live orchids and a surreal art space with ovoids scattered across a floor covered in real moss. These new art spaces can only be experienced here, and explore people’s relationship with nature and the world through digital technology. By incorporating natural light in space, the works reveal different aspects during the day and after sunset.

Floating Flower Garden; Flowers and I are of the Same Root, the Garden and I are One
Artwork: https://planets.teamlab.art/tokyo/ew/ffgarden_planets/

Moss Garden of Resonating Microcosms - Solidified Light Color, Sunrise and Sunset
Artwork: https://planets.teamlab.art/tokyo/ew/resonating_microcosms_mossgarden_planets/

Food and Art: Enjoy vegan ramen in an art space

Vegan Ramen UZU Tokyo, a vegan ramen restaurant originating from Kyoto, opened in October 2021 on the same premises as teamLab Planets. Diners can enjoy ramen in teamLab’s Reversible Rotation - Non-Objective Space artwork space, as well as the Table of Sky and Fire and One Stroke Bench outside of the restaurant. Vegan Ramen UZU Tokyo also has vegan ice cream and various teas that are only available in Tokyo. The restaurant can be visited without entry to teamLab Planets.

Vegan Ramen UZU Tokyo: https://vegan-uzu.com/pages/uzu-tokyo

Public art that can be experienced by all

Universe of Fire Particles Falling from the Sky is a work of public art that depicts flames, on display since April 2021. Flames, which are a phenomenon of light and heat generated by combustion, are expressed as a collection of lines drawn in relation to the flow of combusting gas. The work is displayed outdoors and can be viewed by anyone, regardless of whether or not they enter the museum.

Universe of Fire Particles Falling from the Sky
Artwork: https://planets.teamlab.art/tokyo/ew/universe_fireparticles_falling/

[ teamLab Planets TOKYO DMM ]

teamLab Planets is a museum where you walk through water, and a garden where you become one with the flowers. There are four massive exhibition spaces and two gardens.

By immersing your entire body with other people in these massive artworks, the boundary between the body and the artwork dissolves. The self, others, and the world become continuous, and we explore a new relationship without boundaries between ourselves and the world.

Enter barefoot, immerse your body with others in the artwork spaces, and become one with the world.

[Exhibition details]

teamLab Planets TOKYO DMM
Location: teamLab Planets TOKYO, 6-1-16 Toyosu, Koto-ku, Tokyo

[Opening hours]

(November - January)
Mon - Fri 10:00 - 20:00
Saturdays, Sundays, and holidays 9:00 - 21:00
* December 26 (Mon) - December 30 (Fri), January 2 (Mon) - January 6 (Fri) 9:00 - 21:00
* December 31 (Sat), January 1 (Sun) 9:00 - 20:00
* Last entry is 1 hour before closing

Closed:
December 8 (Thu), January 11 (Wed)

*Opening hours are subject to change. Please check the official website for the latest updates.

Official website: https://planets.teamlab.art/tokyo/jp/
teamLab Planets Highlight Video: https://youtu.be/oiQoe9Ow9o0

*teamLab Planets will be open in Toyosu, Tokyo until the end of 2023.

[Tickets]

Adult: 3,200 yen
Junior high and high school students: 2,000 JPY
Children (4 to 12 years old): 1,000 JPY
3 years old and under: Free
Disability discount: 1,600 JPY

teamLab Planets TOKYO DMM Ticket Store: https://teamlabplanets.dmm.com

[Measures to prevent the spread of COVID-19s]

Please check the link below for details on the infection prevention measures implemented at teamLab Planets:
https://teamlabplanets.dmm.com/covid-19

[Official HP/Social Media]

Official website: https://planets.teamlab.art/tokyo/
Instagram: https://www.instagram.com/teamlab.planets/
Facebook: https://www.facebook.com/TL.Planets/
Twitter: https://twitter.com/teamLabPlanets
#teamLabPlanets

[Food & Shop]

Vegan Ramen UZU Tokyo: https://vegan-uzu.com/pages/uzu-tokyo
teamLab Flower Shop & Art
*Please check the official website for opening hours
*Closed on the same days as teamLab Planets

[New coronavirus measures (applicable to the Food & Shop)]

  • Implementation of regular cleaning and disinfection
  • Seat disinfection after each customer
  • Hand disinfection upon entry
  • Restrictions on the number of people in the space
  • Ensuring sufficient space between seats
  • Employees wear masks
  • Removal of tabletop items
  • Temperature measurement

[Press kit]

https://goo.gl/tQXMLm

[PLANETS Co., Ltd.]

Established in 2017. Operates and manages the facilities of teamLab Planets TOKYO.
Location: Tokyo Nihonbashi Tower 10F, 2-7-1 Nihonbashi, Chuo-ku, Tokyo
Representative: Takumi Nomoto

[teamLab]

teamLab (f. 2001) is an international art collective. Their collaborative practice seeks to navigate the confluence of art, science, technology, and the natural world. Through art, the interdisciplinary group of specialists, including artists, programmers, engineers, CG animators, mathematicians, and architects, aims to explore the relationship between the self and the world, and new forms of perception.

In order to understand the world around them, people separate it into independent entities with perceived boundaries between them. teamLab seeks to transcend these boundaries in our perceptions of the world, of the relationship between the self and the world, and of the continuity of time. Everything exists in a long, fragile yet miraculous, borderless continuity.

teamLab exhibitions have been held in cities worldwide, including New York, London, Paris, Singapore, Silicon Valley, Beijing, and Melbourne among others. teamLab museums and large-scale permanent exhibitions include teamLab Borderless and teamLab Planets in Tokyo, teamLab Borderless Shanghai, and teamLab SuperNature Macao, with more to open in cities including Abu Dhabi, Beijing, Hamburg, Jeddah, and Utrecht.

teamLab’s works are in the permanent collection of the Museum of Contemporary Art, Los Angeles; Art Gallery of New South Wales, Sydney; Art Gallery of South Australia, Adelaide; Asian Art Museum, San Francisco; Asia Society Museum, New York; Borusan Contemporary Art Collection, Istanbul; National Gallery of Victoria, Melbourne; and Amos Rex, Helsinki.

teamLab: https://www.teamlab.art/
Instagram: https://instagram.com/teamlab/
Facebook: https://www.facebook.com/teamLab.inc
Twitter: https://twitter.com/teamLab_net
YouTube: https://www.youtube.com/c/teamLabART

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005639/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye